Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Giovanni Scambia, Anna Fagotti, Marco Petrillo, Barbara Costantini, P. De Iaco, M. Perrone

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Background: To analyze the 5- and 7-year survival outcomes for women with platinum-sensitive recurrent epithelial ovarian cancer (REOC) who underwent secondary cytoreductive surgery (SCS) plus platinum-based hyperthermic intraperitoneal chemotherapy (HIPEC). Methods: From the electronic databases of the Department of Obstetrics and Gynecology at the Catholic University of the Sacred Heart of Rome and of the S. Orsola Hospital, University of Bologna, a consecutive series of REOC patients were selected using the following inclusion criteria: primary platinum-free interval (PFI-1) of 6 months or longer, completeness of secondary cytoreduction score (CC) of 1 or lower, minimum follow-up period of 48 months, Eastern Cooperative Group (ECOG) performance status at recurrence of 1 or less, and platinum-based HIPEC. Progression-free survival (PFS) and post-relapse survival (PRS) were calculated as the time between SCS + HIPEC and secondary recurrence or death, respectively. Results: The final study population included 70 women with platinum-sensitive REOC. The median follow-up time was 73 months (range 48–128 months), and the median PFI-1 was 19 months (range 6–100 months). At the time of recurrence, the median peritoneal cancer index was 7 (range 1–21), and a CC score of 0 was achieved for 62 patients (88.6 %). As the HIPEC drug, we used oxaliplatin in 17 cases (38.6 %) and cisplatin in 43 cases (61.4 %). No postoperative deaths were observed, and the complication rate for grades 3 and 4 disease was 8.6 %. The median PFS duration was 27 months (range 5–104 months), and the 5- and 7-year PRS rates were respectively 52.8 and 44.7 %, (median PRS 63 months). Conclusions: The current study demonstrated favorable 5- and 7-year PRS rates for platinum-sensitive REOC patients undergoing SCS + HIPEC, which encourages the inclusion of patients in randomized clinical trials for definitive conclusions to be drawn.
Original languageEnglish
Pages (from-to)1660-1665
Number of pages6
JournalAnnals of Surgical Oncology
Volume23
DOIs
Publication statusPublished - 2016

Keywords

  • Adenocarcinoma, Clear Cell
  • Adult
  • Aged
  • Combined Modality Therapy
  • Cystadenocarcinoma, Serous
  • Cytoreduction Surgical Procedures
  • Endometrial Neoplasms
  • Female
  • Follow-Up Studies
  • Humans
  • Hyperthermia, Induced
  • Injections, Intraperitoneal
  • Middle Aged
  • Neoplasm Grading
  • Neoplasm Recurrence, Local
  • Neoplasm Staging
  • Oncology
  • Ovarian Neoplasms
  • Platinum
  • Prognosis
  • Retrospective Studies
  • Surgery
  • Survival Rate

Fingerprint

Dive into the research topics of 'Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC)'. Together they form a unique fingerprint.

Cite this